Abeona Therapeutics (NASDAQ:ABEO) Upgraded by StockNews.com to “Hold”

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a research report report published on Monday morning.

Abeona Therapeutics Price Performance

NASDAQ ABEO opened at $7.53 on Monday. The stock has a market capitalization of $205.95 million, a price-to-earnings ratio of -2.92 and a beta of 1.49. Abeona Therapeutics has a one year low of $2.83 and a one year high of $9.01. The business’s fifty day moving average is $7.44 and its 200-day moving average is $5.59.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.13). Research analysts expect that Abeona Therapeutics will post -1.83 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ABEO. Tower Research Capital LLC TRC bought a new stake in shares of Abeona Therapeutics during the 3rd quarter valued at about $43,000. GSA Capital Partners LLP bought a new stake in shares of Abeona Therapeutics during the 3rd quarter valued at about $49,000. Bank of New York Mellon Corp bought a new stake in shares of Abeona Therapeutics during the 2nd quarter valued at about $52,000. Creative Planning bought a new stake in shares of Abeona Therapeutics during the 3rd quarter valued at about $59,000. Finally, Simplex Trading LLC boosted its position in shares of Abeona Therapeutics by 1,889.9% during the 3rd quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 13,418 shares during the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.